Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice
Open accessThe DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
Asthma is a common chronic pulmonary inflammatory disease, featured with mucus hyper-secretion in the airway. Recent studies found that glucagon like peptide-1 (GLP-1) analogs, including liraglutide and exenatide, possessed a potent anti-inflammatory property through a protein kinase A (PKA)-dependent signaling pathway. Therefore, the aim of current study was to investigate the value of GLP-1 analog therapy liraglutide in airway inflammation and mucus secretion in a murine model of ovalbumin (OVA)-induced asthma, and its underlying molecular mechanism. In our study, BALB/c mice were sensitized and challenged by OVA to induce chronic asthma. Pathological alterations, the number of cells and the content of inflammatory mediators in bronchoalveolar lavage fluid (BALF), and mucus secretion were observed and measured. In addition, the mRNA and protein expression of E-selectin and MUC5AC were analyzed by qPCR and Western blotting. Then, the phosphorylation of PKA and nuclear factor-κB (NF-κB) p65 were also measured by Western blotting. Further, NF-κB p65 DNA binding activity was detected by ELISA. OVA-induced airway inflammation, airway mucus hyper-secretion, the up-regulation of E-selectin and MUC5AC were remarkably inhibited by GLP-1 in mice (all p < 0.01). Then, we also found that OVA-reduced phosphorylation of PKA, and OVA-enhanced NF-κB p65 activation and NF-κB p65 DNA binding activity were markedly improved by GLP-1 (all p < 0.01). Furthermore, our data also figured out that these effects of GLP-1 were largely abrogated by the PKA inhibitor H-89 (all p < 0.01). Taken together, our results suggest that OVA-induced asthma were potently ameliorated by GLP-1 possibly through a PKA-dependent inactivation of NF-κB in mice, indicating that GLP-1 analogs may be considered an effective and safe drug for the potential treatment of asthma in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Liraglutide (2 mg/kg) reduced immune cell infiltration and protein expression of E-selectin, TNF-α, IL-4, IL-5, and IL-13 in the lung tissue or bronchoalveolar lavage fluid in an ovalbumin-induced chronic asthma model.”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedThe prevalence of severe refractory asthma
Hekking, P.-P. W., Wener, R. R., Amelink, M., Zwinderman, A. H., Bouvy, M. L., & Bel, E. H. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.042 · Cited by 813
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 1×
“Therefore, these findings, in consistent with the previous studies, indicated that GLP-1R should exist on airway epithelial cells [14,15,31].”
ResultArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“[24] showed that LPS-induced macrophage activation and TNF-α expression was significantly reduced by”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · cited 1×
“[36] determined that exenatide could ameliorate nonalcoholic fatty liver disease”
BackgroundCampos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353 · cited 1×
“Therefore, these findings, in consistent with the previous studies, indicated that GLP-1R should exist on airway epithelial cells [14,15,31].”
ResultcAMP regulation of airway smooth muscle function
Billington, C. K., Ojo, O. O., Penn, R. B., & Ito, S. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.05.007 · Cited by 240
Bao, Z., Guan, S., Cheng, C., Wu, S., Wong, S. H., Kemeny, D. M., Leung, B. P., & Wong, W. S. F. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200809-1516oc · Cited by 226 · cited 2×
“A number of studies proved that macrophages, neutrophils, eosinophils, and lymphocytes were the mainly immunological cells in airway inflammation in asthma [4,8,26].”
BackgroundAbdelsalam, R. M., & Safar, M. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13087 · Cited by 221 · cited 1×
“The amount of data also confirmed that PKA was essential for the modulation of NF-κB activation [28,51].”
BackgroundAndrographolide Protects against LPS-Induced Acute Lung Injury by Inactivation of NF-κB
Zhu, T., Wang, D.-X., Zhang, W., Liao, X.-Q., Guan, X., Bo, H., Sun, J.-Y., Huang, N.-W., He, J., Zhang, Y.-K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056407 · Cited by 210 · cited 1×
“Simultaneously, many studies determined that the de novo synthesis of TNF-α and E-selectin, the critical inflammatory molecules, were mainly regulated by NF-κB activation in ARDS and asthma [27,52,53].”
BackgroundSelf-citation
Cited by
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
Koga, Y., Tsurumaki, H., Aoki‐Saito, H., Sato, M., Yatomi, M., Takehara, K., & Hisada, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061346 · Cited by 165
Emodin suppresses LPS-induced inflammation in RAW264.7 cells through a PPARγ-dependent pathway
Zhu, T., Zhang, W., Feng, S.-J., & Yu, H.-P. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.02.014 · Cited by 141
Self-citationGLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
“Frontiers in Immunology 05 showed that GLP-1R signaling inhibits the innate immune response in animal models of asthma, by the activation of PKA/NF-kB signaling pathway (99) and the decreased eosinophil production of IL-4, IL-8 and IL-13 (39).”
BackgroundPradhan, R., Lu, S., Yin, H., Yu, O. H. Y., Ernst, P., Suissa, S., & Azoulay, L. (2022) · BMJ · doi:10.1136/bmj-2022-071380 · Cited by 111
Toki, S., Goleniewska, K., Reiss, S., Zhang, J., Bloodworth, M. H., Stier, M. T., Zhou, W., Newcomb, D. C., Ware, L. B., Stanwood, G. D., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.043 · Cited by 104
Covid-19 and Diabetes: A Complex Bidirectional Relationship
Muniangi-Muhitu, H., Akalestou, E., Salem, V., Misra, S., Oliver, N. S., & Rutter, G. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.582936 · Cited by 104
Toki, S., Newcomb, D. C., Printz, R. L., Cahill, K. N., Boyd, K. L., Niswender, K. D., & Peebles, R. S. (2021) · Allergy · doi:10.1111/all.14879 · Cited by 88
Zhu, T., Chen, Z., Chen, G., Wang, D., Tang, S., Deng, H., Wang, J., Li, S., Lan, J., Tong, J., et al. (2019) · Mediators of Inflammation · doi:10.1155/2019/4927430 · Cited by 88
“our previous studies, the histological mucus index (the percentage of the mucus-positive area of the whole bronchial epithelium) was recorded [3, 4, 29].”
BackgroundMethodResultSelf-citationMitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., & O'Byrne, P. M. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12860 · Cited by 78
Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds
Insuela, D. B. R., & Carvalho, V. F. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.015 · Cited by 72
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
Lg, S., Дігтяр, Н. І., Селіхова, Л. Г., Кайдашева, Е. І., Shlykova, O. A., Vesnina, L. E., & Кайдашев, І. П. (2019) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2019-0003 · Cited by 81
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients
Rogliani, P., Matera, M. G., Calzetta, L., Hanania, N. A., Page, C. P., Rossi, I., Andreadi, A., Galli, A., Coppola, A., Cazzola, M., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.06.015 · Cited by 69
Ye, J., Zhang, H., He, W., Zhu, B., Zhou, D., Chen, Z., Ashraf, U., Wei, Y., Liu, Z., Fu, Z. F., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf5132 · Cited by 70
Hur, J., Kang, J. Y., Kim, Y. K., Lee, S. Y., & Lee, H. Y. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102003 · Cited by 65
Albogami, Y., Cusi, K. J., Daniels, M. J., Wei, Y. J., & Winterstein, A. G. (2021) · Diabetes Care · doi:10.2337/dc20-1794 · Cited by 63
Hariyanto, T. I., Intan, D., Hananto, J. E., Putri, C., & Kurniawan, A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109031 · Cited by 60
Bloodworth, M. H., Rusznak, M., Pfister, C. C., Zhang, J., Bastarache, L., Calvillo, S. A., Chappell, J. D., Boyd, K. L., Toki, S., Newcomb, D. C., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.01.053 · Cited by 57
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
Wang, W., Mei, A., Qian, H., Li, D., Xu, H., Chen, J., Yang, H., Min, X., Li, C., Cheng, L., et al. (2023) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s393323 · Cited by 53
“In a lipopolysaccharide (LPS)-induced mouse model, GLP-1 expression was reduced in peripheral blood and increased in alveolar lavage fluid and lung tissues, which was inhibited by liraglutide, a GLP-1RA, and was able to suppress LPSinduced lung injury in mice, inhibit polymorphonuclear neutrophil (PMN) extravasation,…”
BackgroundGlucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma
Nguyen, D.-V., Linderholm, A., Haczku, A., & Kenyon, N. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.012 · Cited by 57
Experimental animal models of chronic inflammation
Rafiyan, M., Sadeghmousavi, S., Akbarzadehmoallemkolaei, M., & Rezaei, N. (2023) · Current Research in Immunology · doi:10.1016/j.crimmu.2023.100063 · Cited by 59
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Zhu, T., Li, S., Wang, J., Liu, C., Gao, L., Zeng, Y., Mao, R., Cui, B., Ji, H., & Chen, Z. H. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00227-w · Cited by 54
Self-citationLu, X. C., Xu, C., Dong, J., Zuo, S., Zhang, H., Jiang, C., Wu, J., & Wei, J. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100872 · Cited by 51
Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells
Zhao, H.-J., Jiang, X., Hu, L.-J., Yang, L., Deng, L.-D., Wang, Y.-P., & Ren, Z.-P. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0186 · Cited by 43
Zhu, T., Li, C., Zhang, X., Ye, C., Tang, S., Zhang, W., Sun, J., Huang, N., Wen, F., Wang, D., et al. (2018) · Mediators of Inflammation · doi:10.1155/2018/3601454 · Cited by 42
“The mRNA expression of SP-A and TTF-1 was detected by qPCR [15, 22].”
BackgroundMethodResultInfluentialSelf-citationHuang, J., Yi, H., Zhao, C., Zhang, Y., Zhu, L., Liu, B., He, P., & Zhou, M. (2018) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s175145 · Cited by 43
Liraglutide pretreatment attenuates sepsis-induced acute lung injury
Baer, B., Putz, N. D., Riedmann, K. J., Gonski, S. K., Lin, J., Ware, L. B., Toki, S., Peebles, R. S., Cahill, K. N., & Bastarache, J. A. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00041.2023 · Cited by 46
Pang, Y., Yuan, X., Guo, J., Wang, X., Yang, M., Zhu, J., & Wang, J. (2018) · Journal of Periodontal Research · doi:10.1111/jre.12607 · Cited by 39
Al-Dwairi, A., Alqudah, T., Al-Shboul, O., Alqudah, M., Mustafa, A., & Alfaqih, M. A. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s152835 · Cited by 37
“33 In our study, we used an antibody array membrane as a screening tool to assess the effect of inflammation and GLP-1 co-treatment on the expression of cytokines and chemokines in mouse CSMCs.”
Diabetes, insulin resistance, and asthma: a review of potential links
Wu, T. D. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000738 · Cited by 41
The impact of therapy on the risk of asthma in type 2 diabetes
Rayner, L. H., McGovern, A. P., Sherlock, J., Gatenby, P. A. C., Correa, A., Creagh-Brown, B. C., & de Lusignan, S. (2019) · The Clinical Respiratory Journal · doi:10.1111/crj.13011 · Cited by 36
Zhang, Y., Yuan, X., Wu, Y., Pei, M., Yang, M., Wu, X., Pang, Y., & Wang, J. (2020) · Journal of Dentistry · doi:10.1016/j.jdent.2020.103310 · Cited by 35
Self-citationAlasmari, A. F., Ali, N., Alasmari, F. F., Alanazi, W. A., Alshammari, M. A., Al-Harbi, N. O., Alhoshani, A., Sobeai, H. M. A., Alswayyed, M., Alanazi, M. M., et al. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.03.002 · Cited by 34
“It has been suggested that the protective effects of LIRA is mainly due to its antioxidant property as it has been shown that LIRA treatment reduced oxidative stress and restored the antioxidant enzymes activity (Bianchi et al., 2019; Deng et al., 2018; Rizzo et al., 2015; Zhu et al., 2015).”
The GLP-1 receptor in airway inflammation in asthma: a promising novel target?
Wu, A. Y., & Peebles, R. S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1971973 · Cited by 34
“In a mouse model of asthma, liraglutide and exenatide inhibited OVA-induced airway inflammation via decrease in airway mucus hypersecretion and putative PKAdependent inactivation of nuclear factor-kB [8], while use of”
BackgroundGlucagon‐like peptide‐1 receptor agonists in the era of COVID ‐19: Friend or foe?
Belančić, A., Kresović, A., & Dijan, M. (2021) · Clinical Obesity · doi:10.1111/cob.12439 · Cited by 32
Leonurine attenuates OVA-induced asthma via p38 MAPK/NF-κB signaling pathway
Bai, D., Sun, Y., Li, Q., Li, H., Liang, Y., Xu, X., & Hao, J. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109483 · Cited by 30
Evaluating the glucagon-like peptide-1 receptor in managing asthma
Wu, A. Y., Cahill, K. N., Toki, S., & Peebles, R. S. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000797 · Cited by 30
Wang, B., Chen, T., Li, G., Jia, Y., Wang, J., Li, X., & Chen, Y. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02730-7 · Cited by 31
Pathak, M. P., Patowary, P., Goyary, D., Das, A., & Chattopadhyay, P. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153610 · Cited by 29
Nanotherapeutics in the treatment of acute respiratory distress syndrome
Prasanna, P., Rathee, S., Upadhyay, A., & Sulakshana, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119428 · Cited by 29
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
“Another study indicated that GLP-1RAs such as exenatide and liraglutide effectively improve ovalbumin (OVA)-induced asthma by reducing airway mucus hypersecretion and inflammatory responses in mice through PKA-dependent NF-κB inactivation [248].”
Balk-Møller, E., Windeløv, J. A., Svendsen, B., Hunt, J., Ghiasi, S. M., Sørensen, C. M., Holst, J. J., & Kissow, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz034 · Cited by 22
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Unraveling the Link between Ιnsulin Resistance and Bronchial Asthma
Bartziokas, Κ., Papaioannou, A. Ι., Drakopanagiotakis, F., Gouveri, E., Παπάνας, Ν., & Steiropoulos, P. (2024) · Biomedicines · doi:10.3390/biomedicines12020437 · Cited by 28
“Furthermore, the GLP-1RA liraglutide reduced mucus hypersecretion and airway inflammation in a mouse model of allergic asthma [110].”
BackgroundObesity-associated asthma in childhood
Mangova, M., Lipek, T., Hove, M. V., Körner, A., Kieß, W., Treudler, R., & Prenzel, F. (2020) · Allergologie select · doi:10.5414/alx02178e · Cited by 27
“In addition, improvements in bronchial asthma have been described in a mouse model [88].”
BackgroundInterplay Between the Immune and Endocrine Systems in the Lung: Implications for TB Susceptibility
Webber, T., Ronacher, K., Conradie-Smit, M., & Kleynhans, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.829355 · Cited by 27
Cooper, D. H., Akbarian, N., Aaron, S. D., Luks, V., & Kendzerska, T. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108197 · Cited by 23
Bai, Y., Lian, P., Li, J., Zhang, Z., & Jian, Q. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104645 · Cited by 21
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., Ashour, N. A., & Negm, W. A. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01239-4 · Cited by 19
Guo, J., Chen, X., Wang, C., Ruan, F., Xiong, Y., Wang, L., Abdel-Razek, O. A., Meng, Q., Shahbazov, R., Cooney, R. N., et al. (2023) · Shock · doi:10.1097/shk.0000000000002285 · Cited by 17
The Role of Peptides in Asthma–Obesity Phenotype
Russjan, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063213 · Cited by 21
The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function
Kantreva, K., Katsaounou, P. A., Saltiki, K., Trakada, G., Ntali, G., Stratigou, T., Tzanela, M., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-04033-6 · Cited by 18
Asthma and Hyperglycemia: Exploring the Interconnected Pathways
Narendra, D. K., & Khurana, S. (2024) · Diagnostics · doi:10.3390/diagnostics14171869 · Cited by 18
Yu, Q., Zhu, L., Ding, X., & Lou, Y. (2025) · Bioresources and Bioprocessing · doi:10.1186/s40643-025-00869-6 · Cited by 14
“Moreover, asthma improvement was observed through PKA-dependent inactivation of NF-κB pathway (Zhu et al. 2015).”
Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
Ge, D., Foer, D., & Cahill, K. N. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00211-x · Cited by 14
Hou, L., Zhu, L., Zhang, M., Zhang, X., Zhang, G., Liu, Z., Li, Q., & Zhou, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475638 · Cited by 14
Obesity-related, metabolic asthma: a new role for glucagon-like peptide 1 agonists
Nguyen, D.-V., Linderholm, A., Haczku, A., & Kenyon, N. J. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30051-6 · Cited by 14
Maeda, S., Andoh, T., Onishi, R., Tomoyasu, Y., Higuchi, H., & Miyawaki, T. (2018) · Journal of Anesthesia · doi:10.1007/s00540-018-2548-y · Cited by 13
Melo, F. J., Lopes, P., Estevinho, M. M., & Magro, F. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa324 · Cited by 12
Endogenous inhibitory mechanisms in asthma
Chiarella, S. E., & Barnes, P. J. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100135 · Cited by 13
Jin, Y., Zhang, D., Deng, K., Wu, P., Yang, D., Xie, Z., Qiu, W., & Yu, G. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08837-1 · Cited by 11
Therapeutic Peptides for Treatment of Lung Diseases: Infection, Fibrosis, and Cancer
Li, S., Li, Y., Liu, Y., Wu, Y., Wang, Q., Jin, L., & Zhang, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108642 · Cited by 14
Guo, J., Zhang, X., Pan, R., Zheng, Y., Chen, W., & Wang, L. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2384897 · Cited by 11
Dong, Y., Zhang, X., Yao, C., Xu, R. F., & Tian, X. (2021) · Environmental Toxicology · doi:10.1002/tox.23311 · Cited by 9
Knowledge on Medical Waste Management Among Health Care Personnel: A Report from Turkey
Uzunlulu, G., Uzunlulu, M., Gencer, A., Özdoğru, F., & SEVEN, S. (2022) · Cyprus Journal of Medical Sciences · doi:10.4274/cjms.2020.1107 · Cited by 9
COPD and the burden of multimorbidity: navigating the complexity
Kallieri, M., Hillas, G., Bartziokas, Κ., Loukides, S., & Toumpanakis, D. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2569126 · Cited by 8
The role of hormones in ILC2 ‐driven allergic airway inflammation
Dai, Z., Gong, Z., Wang, C., Long, W., Liu, D., Zhang, H., & Lei, A. (2024) · Scandinavian Journal of Immunology · doi:10.1111/sji.13357 · Cited by 8
“81,82 Specifically, liraglutide, a GLP-1 receptor (GLP-1R) agonist that is utilized in the management of obesity and type 2 diabetes, 83 can hinder ILC2 activation in Alternaria - induced allergic lung inflammation by decreasing IL-33 secretion produced by lung epithelial cells.”
BackgroundDai, G.-M., Wang, J., Chen, Z. H., Ran, Y., Deng, H., Mao, R., & Zhu, T. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001154 · Cited by 8
“88 inflammation were the two most important features of asthma.([3-5]) In the early stage of asthma, the response to the treatments, such as inhaled corticosteroids and long-acting b2-agonist (LABA), was well in most of the patients.”
BackgroundMethodResultSelf-citationSaadat, S., Chow, T. G., Tang, Y., Almandoz, J. P., Messiah, S. E., & Xie, L. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.05.010 · Cited by 6
Wu, X., Wang, J., Zou, T., He, S., Zhong, L., Zhang, Q., Song, Y., Wang, C., & Zhao, C. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105518 · Cited by 6
Self-citationAlshanwani, A. R., Kashour, T., & Badr, A. M. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210809153558 · Cited by 8
GLP-1RAs: antidiabetic drug crossover—new hope for chronic inflammatory airway diseases
Chen, Y., Shen, Y., Shen, H., & Liu, Z. (2026) · Respiratory Research · doi:10.1186/s12931-026-03569-7 · Cited by 5
“Based on preclinical data, Zhu et al. demonstrated in an obesity-associated mouse model of asthma that GLP-1 ameliorates ovalbumin-induced airway inflammation and mucus hypersecretion by disrupting the protein kinase A-dependent nuclear factor-κB signaling pathway [61].”
Gu, Y., Yao, L., Jiang, T., & Che, H. (2022) · Foods · doi:10.3390/foods11233758 · Cited by 5
Cazzola, M., Hanania, N. A., Page, C. P., Calzetta, L., Matera, M. G., & Rogliani, P. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2514607 · Cited by 6
“In animal models, GLP-1 administration reduced lung protein excretion of IL-4, IL-5, IL-13, and IL-33, cytokines central to asthma exacerbations [135].”
Potential association between obstructive lung diseases and cognitive decline
Figat, M., Wiśniewska, A., Plichta, J., Miłkowska-Dymanowska, J., Majewski, S., Karbownik, M. S., Kuna, P., & Panek, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1363373 · Cited by 7
Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System
Ji, X.-J., Hao, J.-W., Li, G., Dong, N., Wang, X., Zhou, M., Zhang, Q., & Yao, Y.-M. (2019) · Mediators of Inflammation · doi:10.1155/2019/2750528 · Cited by 5
“Meanwhile, it downregulated TNF-α and monocyte chemoattractant protein-1 (MCP-1) in macrophages [15] and in the airway of asthma mice [24] through inactivation of nuclear factor kappa B (NF-κB) [15].”
BackgroundImpact of Oral Antidiabetics Agents in the Prevention of COPD Exacerbations
Gonçálves, J. M. F., & Golpe, R. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.12.004 · Cited by 5
Effects of Hypoglycemic Agents on Pulmonary Diseases: A Comprehensive Narrative Review
Yang, Y., Wang, K., & CHEN, S. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s556790 · Cited by 4
“92 Crucially, clinical evidence from the LIRALUNG trial, which utilized a short treatment duration specifically designed to minimize weight loss, demonstrated that liraglutide still improved lung function and alveolar-capillary integrity, strongly supporting the existence of direct…”
InfluentialInvestigational approaches for unmet need in severe asthma
Watchorn, D. C., & Menzies-Gow, A. N. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2096593 · Cited by 4
State of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma
Gomez, D. R., Swartzman, I., Linderholm, A., Cummings, B. P., Zeki, A. A., Sundar, K. M., & Kenyon, N. J. (2025) · Lung · doi:10.1007/s00408-025-00861-z · Cited by 3
GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads
O’Brien, H., Franciosi, A. N., & Butler, M. W. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001249 · Cited by 3
Pharmacological interactions between asthma and T2DM therapies: clinical and metabolic implications
Matera, M. G., Page, C. P., Calzetta, L., Rogliani, P., & Cazzola, M. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2632668 · Cited by 3
“In murine models of allergic asthma, GLP-1RAs reduce Th2 cytokines (IL-4, IL-5, IL-13, IL-33), airway inflammation, mucus hypersecretion, and AHR by inhibiting the NLRP3 inflammasome, suppressing NF-κB, and activating PKA [143–145].”
Liu, Q., Dong, J., Liu, J., Ji, C., Zhou, H., Dai, J., Hong, A., & Ma, Y. (2022) · Academic Journal of Science and Technology · doi:10.54097/ajst.v1i3.392 · Cited by 3
Zhu, T., Shi, C., Li, H., He, J., Yang, Y., Wang, Q., Deng, X., Wu, Y., Wang, J., Zhao, Y., et al. (2018) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2018.10.09 · Cited by 4
Self-citationAsthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
Watchorn, D. C., O'Shea, D. B., & Butler, M. W. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202011-4162le · Cited by 4
Sadhu, P., Kumari, M., Rajput, H. S., Patel, V. P., Rathod, F., Shah, N. V., & Seth, A. K. (2024) · Current Nanomedicine · doi:10.2174/0124681873285123240206094443 · Cited by 2
Gong, Y., Du, F., Yao, Y., Wang, H., Wang, X., Xiong, W., Wang, Q., He, G., Chen, L., Du, H. D., et al. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.70001 · Cited by 7
Self-citationInduced Sputum Transcriptomics Profile and Serum C3 are Associated with Asthma Severity
Du, F., Wang, H., Chen, Z. H., Xiong, W., Wang, Q., Li, B., Li, R., Li, L., Shen, Y., & Zhu, T. (2025) · Journal of Asthma and Allergy · doi:10.2147/jaa.s517140 · Cited by 2
Self-citationBalk-Møller, E., Hebsgaard, M., Lilleør, N. B., Møller, C. H., Goetze, J. P., & Kissow, H. (2022) · Frontiers in Transplantation · doi:10.3389/frtra.2022.1082634 · Cited by 1
Influence of antidiabetic drugs on the course of bronchial asthma
Салухов, В. В., Анатольевич, Х. М., Rudakov, Y. V., Nikolaev, A. V., Chugunov, A. A., & Ryazanova, K. M. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-208 · Cited by 1
The Role of GLP-1 Analogues in the Treatment of Obesity-Related Asthma Phenotype
Radzik-Zając, J. (2025) · Biomedicines · doi:10.3390/biomedicines13112610 · Cited by 1
Bobok, N., & Halushko, O. A. (2025) · Problems of ageing and longevity (Ukraine) · doi:10.71012/pro-ageing-2025-4-05 · Cited by 1
Mah, J., Eng, P. C., Izzi‐Engbeaya, C. N., & Finney, L. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2625967 · Cited by 2
“Similarly, in ovalbumin-induced asthma mouse models, liraglutide attenuated airway inflammation and mucus hypersecretion, while in lipopolysaccharide-induced pulmonary inflammation, liraglutide significantly reduced inflammatory responses [98,99].”
Patel, I., Chai, Y.-H., Wang, Z.-Q., Xu, H., Zhang, J., Simó, R., Tang, X., & Zhou, J. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261437346 · Cited by 1
Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders
Russjan, E., Zając, D., & Kaczyńska, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135803 · Cited by 1
“Zhu et al. demonstrated that in a mouse model of ovalbumin (OVA)-induced asthma, liraglutide reduced airway inflammation and mucus secretion, which was probably related to protein kinase A (PKA)-dependent inactivation of the NF-κ B signaling pathway [89].”
Clinical and basic studies of GLP-1 receptor agonists for the treatment of diabetes in China
Hong, T., Liu, J., & Wei, R. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00030 · Cited by 1
Regulation of Immune Responses during Airway Inflammation
Bloodworth, M. H. (2017) · ProQuest Demo Repository
OBESITY AS A RISK FACTOR IN COVID-19 AND THE POSSIBLE EFFECT OF LIRAGLUTIDE THERAPY
Khodier, S. M., Ibrahim, I. A., Saleh, S. Y., & El-Beltagy, M. A. (2020) · Journal of Critical Reviews
Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico
Costanzo, G., & Frasca, F. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01064-x
Metadata
- Authors
- Zhu, T., Wu, X.-L., Zhang, W., & Xiao, M.
- Affiliations
- West China Hospital of Sichuan University (CN)
- Department of Respiratory Medicine, and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, West China Hospital of Sichuan University, Chengdu 610041, China
- First Affiliated Hospital of Chengdu Medical College (CN)
- Corresponding author
- Xiao, Min
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-08-26
- Volume
- 16
- Issue
- 9
- Pages
- 20195-20211
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4613197
- OpenAlex
- W1915288020
- Cited by
- 106
- References
- 58
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 10 · 2023: 10 · 2022: 13 · 2021: 13 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 5 · 2016: 4
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Applying Fundamental Research Foundation of Sichuan Province of China (2013JY0032)
- China Postdoctoral Science Foundation (2014M552369)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, liraglutide, asthma, airway inflammation, mucus hypersecretion, ovalbumin-induced asthma, protein kinase A, NF-κB signaling, NF-κB p65, E-selectin, MUC5AC, H89, anti-inflammatory therapy
- MeSH terms
- Animals, Asthma, Bronchoalveolar Lavage Fluid, Disease Models, Animal, Leukocyte Count, Leukocytes, Mucus, Ovalbumin, Signal Transduction, Cytokines, NF-kappa B, Cyclic AMP-Dependent Protein Kinases, Inflammation Mediators, E-Selectin, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.